Gabapentin
- Product NDC
- 81033-123
- Requested package NDC
- 81033-123-44
- 11-digit product format
- 810330123
- Labeler code
- 81033
- Product ID
- 81033-123_3f2ba3d6-6087-eaf2-e063-6294a90a7642
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Gabapentin
- Dosage form
- SOLUTION
- Route
- ORAL
- Labeler
- Kesin Pharma Corporation
- Application
- ANDA091286
- Marketing category
- ANDA
- Marketing start
- 2025-08-06
- Substance
- GABAPENTIN
- Active strength
- 50 mg/mL
- Pharmacologic classes
- Decreased Central Nervous System Disorganized Electrical Activity [PE]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A091286-001 | GABAPENTIN | GABAPENTIN | 250MG/5ML | SOLUTION / ORAL | AA | 2016-03-14 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A091286-001 | AA |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A091286-001 | GABAPENTIN | 250MG/5ML | SOLUTION / ORAL | AA | 2016-03-14 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A091286-001 | AA | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Gabapentin | GABAPENTIN | Ajenat Pharmaceuticals LLC | 02304deb-7b4a-452f-9b1a-64ca0aedbcc2 | 2025-12-29 | Warnings, Adverse reactions | 091286 ANDA091286 |
| Gabapentin | GABAPENTIN | JVET PHARMACEUTICALS LLC | 63a5fc6d-ca57-4726-b70d-805ac023d959 | 2025-12-10 | Warnings, Adverse reactions | 091286 ANDA091286 |
| Gabapentin | GABAPENTIN | Kesin Pharma Corporation | 4470a567-93a6-a293-e063-6394a90affc1 | 2025-11-25 | Warnings, Adverse reactions | 091286 ANDA091286 81033-123 |
| Gabapentin | GABAPENTIN | Kesin Pharma Corporation | 3f2ba3d6-6086-eaf2-e063-6294a90a7642 | 2025-09-19 | Warnings, Adverse reactions | 091286 ANDA091286 81033-123-44 81033-123 81033012344 |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Gabapentin
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| GABAPENTIN | 50 mg/mL |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 6CW7F3G59X | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 283523 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 3f2ba3d6-6086-eaf2-e063-6294a90a7642 | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| cdc2ae60-922e-452d-a42f-787fe4e2ed06 | Product name | 1 | 20250123 |
| 7059096a-4b9f-36c2-db50-bb5c723e6e9e | Product name | 2 | 20250114 |
| fa3f0129-3502-889f-f424-3a37727959e7 | Product name | 9 | 20181206 |
| 77d89e4c-f57f-326d-d7aa-787f8eebbd2b | Product name | 1 | 20140508 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 81033-123-05 | Gabapentin | 5 mL in 1 CUP, UNIT-DOSE | SOLUTION | 5 | 1 | |
| 81033-123-16 | Gabapentin | 473 mL in 1 BOTTLE | SOLUTION | 473 | 1 | |
| 81033-123-44 | Gabapentin | 40 in 1 CARTON | SOLUTION | 40 | 1 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 81033-123-05 | ML - Milliliter | 81033-123 | bbd6a009-e04a-467c-b980-f11b13656e0c | 1 | 2025-10-14 |
| 81033-123-44 | ML - Milliliter | 81033-123 | 891b43ca-9cec-436e-9073-a34c9c0f7104 | 1 | 2025-10-14 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 283523 | gabapentin 250 MG in 5 mL Oral Solution | PSN | 3f2ba3d6-6086-eaf2-e063-6294a90a7642 | 1 |
| 283523 | gabapentin 250 MG in 5 mL Oral Solution | PSN | 4470a567-93a6-a293-e063-6394a90affc1 | 1 |
| 283523 | gabapentin 50 MG/ML Oral Solution | SCD | 3f2ba3d6-6086-eaf2-e063-6294a90a7642 | 1 |
| 283523 | gabapentin 50 MG/ML Oral Solution | SCD | 4470a567-93a6-a293-e063-6394a90affc1 | 1 |
| 283523 | gabapentin 250 MG per 5 ML Oral Solution | SY | 3f2ba3d6-6086-eaf2-e063-6294a90a7642 | 1 |
| 283523 | gabapentin 250 MG per 5 ML Oral Solution | SY | 4470a567-93a6-a293-e063-6394a90affc1 | 1 |
| 283523 | gabapentin 300 MG per 6 ML Oral Solution | SY | 3f2ba3d6-6086-eaf2-e063-6294a90a7642 | 1 |
| 283523 | gabapentin 300 MG per 6 ML Oral Solution | SY | 4470a567-93a6-a293-e063-6394a90affc1 | 1 |
| 283523 | gabapentin 500 MG per 10 ML Oral Solution | SY | 3f2ba3d6-6086-eaf2-e063-6294a90a7642 | 1 |
| 283523 | gabapentin 500 MG per 10 ML Oral Solution | SY | 4470a567-93a6-a293-e063-6394a90affc1 | 1 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 81033-123-44 | 81033012344 | 40 CUP, UNIT-DOSE in 1 CARTON (81033-123-44) / 5 mL in 1 CUP, UNIT-DOSE (81033-123-05) | 2025-09-01 | No | No | Current |